Therapy of murine cutaneous leishmaniasis by DNA vaccination

Vaccine

Volumn 18, Issue 26, 2000, Pages 3011-3017

  Handman, Emanuela ^c   Noormohammadi, Amir H ^a   Curtis, Joan M ^c   Baldwin, Tracey ^c   Sjölander, Anders ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

^c NONE

Author keywords

Interferon gamma; Parasite Surface Antigen 2 vaccine; Th1 Th2 responses; Therapeutic DNA vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; MEMBRANE ANTIGEN; PARASITE ANTIGEN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE RESISTANCE; FEMALE; INTERFERON PRODUCTION; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; STRAIN DIFFERENCE;

EID: 0034237654     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00109-2     Document Type: Article

References (25)

1. Modabber F. Development of vaccines against leishmaniasis. Scand. J. Infect. Dis. 76:1990;72-78.
2. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:1991;2763-2770.
3. Gradoni L., Gramiccia M. Leishmania infantum tropism: strain genotype or host immune status? Parasitol. Today. 10:1994;264-270.
4. Jaffe C.L., Rachamim N., Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J. Immunol. 144:1990;699-706.
5. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:1988;3272-3279.
6. McMahon-Pratt D., Rodriguez D., Rodriguez J.-R., Zhang Y., Manson K., Bergman C., Rivas L., Rodriguez J.F., Lohman K.L., Ruddle N.H., Esteban M. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 61:1993;3351-3359.
7. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., Scheerlinck J.-P.Y. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect. Immun. 63:1995;4261-4267.
8. Sjölander A., Baldwin T.M., Curtis J.M., Lövgren Bengtsson K., Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine. 16:1998;2077-2084.
9. Carson D.A., Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 186:1997;1621-1622.
10. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:1997;2340-2344.
11. Sjölander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis. J. Immunol. 160:1998;3949-3957.
12. Handman E., Hocking R.E., Mitchell G.F., Spithill T.W. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol. Biochem. Parasitol. 7:1983;111-126.
13. Handman E., Osborn A.H., Symons F., van Driel R., Cappai R. The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle. Mol. Biochem. Parasitol. 74:1995;189-200.
14. Murray P.J., Spithill T.W. Variants of a Leishmania surface antigen derived from a multigenic family. J. Biol. Chem. 266:1991;24477-24484.
15. Mitchell G.F. Murine cutaneous leishmaniasis: resistance in reconstituted nude mice and several F1 hybrids infected with Leishmania tropica major. J. Immunogenetics. 10:1983;395-412.
16. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:1995;151-177.
17. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
18. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:1989;59-72.
19. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA. 88:1991;7011-7015.
20. Morris L., Troutt A.B., McLeod K.S., Kelso A., Handman E., Aebischer T. Interleukin-4 but not interferon-γ production correlates with the severity of disease in murine cutaneous leishmaniasis. Infect. Immun. 61:1993;3459-3465.
21. + cells secreting IL-4. Int. Immunol. 5:1993;761-767.
22. Scott P., Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9:1997;285-291.
23. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:1991;3149-3155.
24. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1993;1505-1509.
25. Xu D., Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp 63 of L. major. Immunology. 84:1995;173-176.